Systematic Review Confirms Semaglutide, Tirzepatide, and Dapagliflozin Resolve MASH and Improve Fibrosis
Background
Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease that can lead to advanced fibrosis, cirrhosis, and hepatocellular carcinoma. Despite its high global prevalence, effective pharmacological therapies for MASH remain limited, often relying on lifestyle modifications. Incretin-based therapies, such as glucagon-like peptide-1 receptor agonists (GLP-1RAs), and sodium-glucose cotransporter-2 (SGLT2) inhibitors, initially developed for type 2 diabetes and obesity, have demonstrated pleiotropic metabolic benefits, prompting their investigation as potential treatments for MASH by targeting underlying metabolic dysfunction.
Study Design
This systematic review critically evaluated recent clinical evidence on emerging metabolic therapies for MASH or metabolically associated fatty liver disease (MASLD). Researchers included 12 clinical studies, comprising randomized clinical trials and other relevant clinical studies, that investigated SGLT2 inhibitors, incretin-based therapies (e.g., semaglutide, tirzepatide), and other metabolic agents. The primary outcomes of interest were comprehensive metabolic parameters, hepatic outcomes related to steatosis and disease activity, and crucial histological endpoints when available, alongside safety profiles.
Results
The systematic review identified compelling evidence for several agents. In trials with histological endpoints, semaglutide consistently demonstrated significant efficacy. A phase 3 trial showed semaglutide achieved steatohepatitis resolution without worsening of fibrosis in 62.9% of patients versus 34.3% with placebo (p < 0.001). A separate phase 2 trial reported NASH resolution in 59% versus 17% with placebo (p < 0.001), though without significant fibrosis improvement (43% versus 33%; p = 0.48).
Key Findings
- Semaglutide (phase 3) achieved MASH resolution without fibrosis worsening in 62.9% vs 34.3% placebo (p < 0.001).
- Tirzepatide resolved MASH without fibrosis worsening in 44-62% vs 10% placebo (p < 0.001 for all doses).
- Tirzepatide also improved fibrosis in 51-55% of patients versus 30% with placebo.
- Dapagliflozin improved MASH without fibrosis worsening in 53% vs 30% (p = 0.006).
- Overall, metabolic therapies improved body weight, hepatic steatosis, glycemic parameters, and disease activity.
Why It Matters
This systematic review provides crucial validation for the use of incretin-based therapies and SGLT2 inhibitors in managing MASH, marking a significant shift in treatment paradigms. Clinicians now have robust evidence to consider these agents for patients with MASH, particularly those with co-existing metabolic conditions like type 2 diabetes or obesity. The demonstrated ability of semaglutide, tirzepatide, and dapagliflozin to achieve histological resolution of steatohepatitis and improve fibrosis suggests a potential to halt or even reverse disease progression, reducing the risk of cirrhosis and liver-related complications. This moves beyond purely lifestyle interventions, offering targeted pharmacological strategies that could be integrated into existing protocols for comprehensive metabolic health management.
mash
masld
semaglutide
tirzepatide
dapagliflozin
glp-1-agonist